Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings

被引：0
|
作者：
Mok, S. [1 ]
Tay, Y. [1 ]
Ng, D. [1 ]
机构：
[1] Singapore Gen Hosp, Singapore, Singapore
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P603
引用
收藏
页码：S532 / S532
页数：1
相关论文
共 50 条
  • [41] A Prospective study of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE and Concurrent Capecitabine in Metastatic Paragangliomas
    Ballal, S.
    Yadav, M. P.
    Yadav, D.
    Bal, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S184 - S184
  • [42] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
    Lisa Bodei
    Marta Cremonesi
    Chiara M. Grana
    Nicola Fazio
    Simona Iodice
    Silvia M. Baio
    Mirco Bartolomei
    Dario Lombardo
    Mahila E. Ferrari
    Maddalena Sansovini
    Marco Chinol
    Giovanni Paganelli
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 2125 - 2135
  • [43] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177Lu) Is Effective and Safe in Patients with Pretreated Metastatic Neuroendocrine Tumors: Data from Spanish SEPTRALU Registry
    Bello, P.
    Jimenez-Fonseca, P.
    Percovich, J. C.
    Anido Herranz, U.
    Gajate, P.
    Castellon, M.
    Estorch, M.
    Gonzalez, E.
    Field, C.
    Garcia Alonso, P.
    Carmona-Bayonas, A.
    Mitjavila, M.
    NEUROENDOCRINOLOGY, 2019, 108 : 198 - 198
  • [44] Understanding The Radiobiology Of Targeted Radionuclide Therapy With 177lu-dotatate
    Delbart, W.
    Wimana, Z.
    Vercruyssen, M.
    Meuleman, N.
    Ghanem, G.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S13 - S14
  • [45] FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) after Peptide Receptor Radionuclide Therapy with 177Lu-Dotatate (Lu-PRRT)
    Sansovini, M.
    Stefano, S.
    Ianniello, A.
    Nicolini, S.
    Fantini, L.
    Bongiovanni, A.
    Di Iorio, V
    Sarnelli, A.
    Monti, M.
    Paganelli, G.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 138 - 138
  • [46] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
    Jahn, Ulrika
    Ilan, Ezgi
    Sandstrom, Mattias
    Lubberink, Mark
    Garske-Roman, Ulrike
    Sundin, Anders
    CANCERS, 2021, 13 (05) : 1 - 15
  • [47] Peptide Receptor Radionuclide Therapy (PRRT) in Radioiodine-Refractory Thyroid Cancer. A Case Report of Significant Response to 177Lu-Dotatate Treatment
    Ataei, S.
    Aryiana, K.
    Mostafavi, S.
    Esmatinia, M.
    Kosari, H. Mohammad Zadeh
    Aghaei, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S101 - S101
  • [48] NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Hope, Thomas A.
    Abbott, Amanda
    Colucci, Karen
    Bushnell, David L.
    Gardner, Linda
    Graham, William S.
    Lindsay, Sheila
    Metz, David C.
    Pryma, Daniel A.
    Stabin, Michael G.
    Strosberg, Jonathan R.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (07) : 937 - 943
  • [49] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy; Gender Differences in Small Intestinal and Pancreatic Neuroendocrine Tumors
    Jahn, U. M. M.
    Jahn, U. M.
    Ilan, E.
    Sandstrom, M.
    Garske-Roman, U.
    Velikyan, I.
    Fross-Baron, K.
    Lubberink, M.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S61 - S62
  • [50] Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
    Ilan, Ezgi
    Sandstrom, Mattias
    Wassberg, Cecilia
    Sundin, Anders
    Garske-Roman, Ulrike
    Eriksson, Barbro
    Granberg, Dan
    Lubberink, Mark
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 177 - 182
12345